logo

For the Inventor, By the Inventor

Chigasaki, Japan

Masahiro Sakaitani

This inventor holds 11 USPTO granted patents and 3 EPO patents. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Basilea Pharmaceutica Ag, Nissan Chemical Industries Limited. Active years: 2002-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Sakaitani. Retrieved from https://idiyas.com/inventor/masahiro-sakaitani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 72.7

 

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 285(Granted Patents)


Location History:

  • Chigasaki, JP (2002 - 2008)
  • Shizuoka, JP (2011)
  • Kamakura, JP (2011 - 2013)
  • Hokkaido, JP (2018)

Company Filing History:

goldMedal6 out of 987 
 
Chugai Seiyaku Kabushiki Kaisha
 patents
silverMedal5 out of 72 
 
Basilea Pharmaceutica Ag
 patents
bronzeMedal1 out of 1,235 
 
Nissan Chemical Industries Limited
 patents
4. 1 out of 1 
 
Sakai Toshiyuki
 patent
5. 2 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 2002-2018

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 10005739 - Quinazolinone and isoquinolinone derivative (2018-06-26),
2. 8569378 - p27 protein inducer (2013-10-29),
3. 8278465 - Coumarin derivative having antitumor activity (2012-10-02),
4. 7943748 - Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes (2011-05-17),
5. 7897792 - Coumarin derivative having antitumor activity (2011-03-01),
6. 7879887 - α-amino acid derivatives and medicaments containing the same as an active ingredient (2011-02-01),
7. 7459561 - N-substituted carbamoyloxyalkyl-azolium derivatives (2008-12-02),
8. 7189858 - N-phenyl substituted carbamoyloxyalkyl-azolium derivatives (2007-03-13),
9. 7151182 - Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives (2006-12-19),
10. 6812238 - N-substituted carbamoyloxyalkyl-azolium derivatives (2004-11-02),
11. 6489440 - Cyclic compounds (2002-12-03),

Title: Masahiro Sakaitani: Innovator in Pharmaceutical Chemistry

Introduction

Masahiro Sakaitani is a prominent inventor based in Chigasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 11 patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Sakaitani has developed quinazolinone and isoquinolinone derivatives. These compounds are represented by a specific formula and include pharmaceutically acceptable salts. Another notable invention is a p27 protein inducer, which comprises a compound represented by a general formula as an active ingredient. This invention aims to provide a new approach to inducing p27 protein, which plays a crucial role in cell cycle regulation.

Career Highlights

Sakaitani has worked with several reputable companies throughout his career. Notably, he has been associated with Chugai Pharmaceutical Co., Ltd. and Basilea Pharmaceutica AG. His experience in these organizations has allowed him to advance his research and contribute to the development of new pharmaceutical products.

Collaborations

Sakaitani has collaborated with notable colleagues in his field, including Eisaku Mizuguchi and Nobuo Shimma. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Masahiro Sakaitani is a distinguished inventor whose contributions to pharmaceutical chemistry are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…